WEDNESDAY **MAY 22**

Welcome & Lunch

12:00

13:00	L.A.M.P Industry workshops see details page 8 LIVERPOOL AORTIC MASTERS PROGRAM	
18:00	Adjournment	
THINK	cenav	
THURSDAY		
MAY 23		
08:00	Welcome & Coffee	
08:30	Welcome John Brennan & Rao Vallabhaneni	
08:35	Introduction of technology: We fail again! Chairmen: Mike Jenkins, Eric Verhoeven	
08:35	Rapid introduction of unproven technology: EVAS - a case study. Seamus Harrison	
08:44	Who picks up the pieces when the balloon of "promising technology" bursts? Rachel Bell	
08:53	The ice is thinner than the skaters think! Reminding physicians of their duties when introducing new technology. <i>Ruth Steinholtz</i>	
09:02	How would a perfect device overcome the problems? Bijan Modarai	
09:11	How should we introduce the next Wondergraft? John Brennan	
09:20	Discussion	
10:00	Coffee break	
10:30	Why is NICE thinking of turning NASTY? (No Aneurysm Stenting from Today) Chairmen: Bruce Campbell, Tilo Kölbel	
10:30	NICE guidelines - how are they generated? Why do they matter within & outside UK? Bruce Campbell	
10:39	Can you accept EVAR trials 10-year results and still justify EVAR for all-comers? Janet Powell	
10:48	It is all about (the health) economics. Is it really? Jonathan Michaels	
10:57	Square pegs in round holes: aneurysm screening and ruptured aneurysms in the 'NASTY' era. Meryl Davis	
11:06	Square pegs in round holes: patient choice and high risk patients in the 'NASTY' era. Francesco Torella	
11:15	The evidence NICE ignored: review of RCT evidence is not enough and why? Jan Blankensteijn	
11:24	Same evidence base, different guidelines; what is correct? Joshua Adams	
11:33	Personalised decision making for AAA. Rao Vallabhaneni	
11:42	Discussion / light skirmish!	
12:30	Lunch	

01:30	Arch of aorta & thoracic aorta Chairmen: <i>Manoj Kuduvalli, Firas Mussa</i>
01:30 01:39 01:48 01:57	Arch branch TEVAR has come of age: series of 70. <i>Tilo Kölbel</i> Cerebral protection during total arch fenestrated TEVAR. <i>George Joseph</i> When should you consider OR with FET? <i>Mark Field</i> Endovascuar treatment of Type A dissection: lessons from TAVI. <i>Suneil Aggarwal</i>
02:06 02:15 02:24	What is the state of the art for Type A dissection? <i>Christoph Nienaber</i> LSA - when and why should we bother? <i>Mike Jenkins</i> Discussion
03:00	Coffee break
03:30	Complex abdominal EVAR Chairmen: Rachel Bell, John Brennan
03:30 03:39 03:48 03:57 04:06 04:15 04:24 04:33 04:42	World experience of the snorkel/chimney technique: report from the PERICLES registry. David Ormesha How to get the best use of EndoAnchors: critical analysis of >500 implants. Jean Paul de Vries Latest on the re-constrainable platform of FEVAR. Robin Williams Developments in the Gianturco-Z stent based platform of FEVAR. Tim Resch Target vessel stents - how to match stent for the purpose. Simon Neequaye Pursuing the perfect seal zone: balance between operative safety & long-term efficacy. Eric Verhoeve. Increased complexity of FEVAR equals increased complications. Martin Austerman Intelligent image fusion for intraoperative navigation. Tom Carrell Outcomes in EVAR, FEVAR and BEVAR: are there differences between men & women? Thanos Katsargyri Steerable sheaths for target vessel stent deployment: an expert view & results. Tilo Kölbel
0E-16	Discussion and slags of day 1

05:10 Discussion and close of day 1

